Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer

Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

Read the whole article on Physorg

More from Physorg